Wybierz wielkość
Informacje o tej pozycji
Nazwa produktu
Cellicon® Filter Assembly with Durapore® Membrane, filtration area 0.01 m2
material
PET support
PVDF
polyester support
agency
meets USP Biological Reactivity Test for class VI plastics (family component materials)
sterility
sterile; γ-irradiated (level of 25-40kGy)
flow rate measuring range
10 L/min (/m2)
parameter
1 psi max. reverse press. exposure at 25 °C
1-2.5 L process volume
15 psi at 25 °C (max. burst pressure)
5 psi max. inlet pressure at 25 °C
filtration area
0.01 m2
membrane filtration area
0.01 m2
pore size
5 μm pore size
storage temp.
15-25°C
Quality Level
Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów
Application
Seed Train Perfusion
Features and Benefits
General description
Other Notes
Legal Information
Certyfikaty analizy (CoA)
Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.
Masz już ten produkt?
Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.
Produkty
This page describes the financial and operational advantages offered by the Cellicon® Cell Retention Device in an N-1 perfusion process at the 2,000 L scale in comparison to a cell retention device from another supplier.
This page describes the design attributes of the Cellicon® filter assembly for cell retention and how they simplify scale-up of intensified upstream processes.
This page summarizes several performance attributes and scalability data for Mobius® iFlex Bioreactors, single-use, stirred tank systems designed to support traditional and intensified fed-batch and perfusion cell culture applications.
How the Cellicon® filter and controller enables seamless adoption of a perfused N-1 seed train step into the cell expansion process.
Powiązane treści
Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.
Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.
Learn more on mAB bioreactor production, and the products you need for this step.
Dowiedz się więcej o produkcji w bioreaktorze mAB i produktach potrzebnych do tego etapu.
Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.
Skontaktuj się z zespołem ds. pomocy technicznej